Bharath Kumar
Homi Bhabha National Institute(IN)Tata Memorial Hospital(IN)Novo Nordisk (India)(IN)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Diverse Aspects of Tourism Research, Colorectal Cancer Surgical Treatments
Most-Cited Works
- → A minimal common outcome measure set for COVID-19 clinical research(2020)1,774 cited
- → High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial(2025)16 cited
- → Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials(2025)3 cited
- → Learning curve and proficiency assessment for gynecological brachytherapy amongst radiation oncology trainees in India: Results from a prospective study(2025)2 cited
- → Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5(2025)2 cited
- → Simultaneous integrated boost intensity‐modulated radiation therapy targeting clinically involved extramesorectal lymph nodes in locally advanced rectal cancer: A retrospective study(2025)1 cited
- → PO0216(2024)
- → High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight/obesity: a randomized, placebo-controlled, phase 2 trial(2025)
- → Author response for "Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the <scp>ONWARDS</scp> 1–5 trials"(2025)